Ribosomal Protein S 15 A Promotes Malignant Transformation and Predicts Poor Outcome in Colorectal Cancer Through Misregulation of P 53 Signaling Pathway
JINGwEN CHEN,YE WEI,QINGYANG FENG,LI REN,wENJu CHANG,DExIANG ZHu,YI Tuo,wENTAo TANG,JIANmIN xu,xINYu QIN
2016-01-01
Abstract:Ribosomal protein S15A (RPS15A), which has been identified as a highly conserved 40S ribosomal protein, is essential for cell survival and proliferation. The present study evaluated the functional role of RPS15A in colorectal cancer (CRC), and our investigation found that RPS15A was highly expressed in a cohort of human CRC. High RPS15A expression was associated with older age (P=0.035), not receiving preoperative neoadjuvant treatment (P=0.048), higher primary pN stage (P=0.007) and slightly more synchronous distant metastases (P=0.058). The Cox univariate and multivariate hazard regression analysis revealed that higher expression of RPS15A led to a reduction of overall survival rate in CRC, indicating that enhanced RPS15A expression functions as an independent risk factor for the prognosis of CRC patients (P<0.001). Cell based analysis showed that RPS15A was widely expressed in human CRC cell lines. Knockdown of RPS15A significantly suppressed cell proliferation and colony formation in HCT116 and DLD-1 cells, and induced cell cycle arrest at G0/G1 phase. GeneChip analysis suggested that knockdown of RPS15A might affect the p53 signaling pathway. Further study indicated that RPS15A knockdown upregulated p53 and p21 expression whereas downregulated CDK1 expression. In summary, the present study identified RPS15A as a novel univariate prognostic factor predicting a poor outcome in CRC patients. The RPS15A overexpression induced by malignant transformation of CRC might function through the p53 signaling pathway. Introduction Colorectal cancer (CRC) is one of the leading causes of death in western countries (1), and the incidence is still increasing. Approximately 70% of patients with CRC are >65 years while the disease is rare under the age of 45 (2). Advancements in surgery and perioperative therapies have significantly improved the survival rate in patients with CRC (3). However, the possibility of tumor recurrence remains high even after surgical therapy and it depends on the stage of cancer at the time of diagnosis. Recently, molecular targeting, a novel therapeutic strategy, has been widely researched and applied in the treatment of CRC. Ribosomal proteins (RPs) play an important role in forming the majority of cellular proteins and are considered to be indispensable for cell growth (4). RP genes have been linked, either directly or indirectly, to various diseases including cancer. Eukaryotic ribosomes are composed of ~79 different ribosomal proteins (5). Even though the functions of RPs have not been fully investigated, quantitative deficiencies of RP genes have been suggested to contribute to the growth retardation and abnormalities (6,7). Ribosomal protein S15A (RPS15A) is a highly conserved 40S ribosomal protein which promotes the binding of capped mRNA to the small ribosomal subunit at the early stages of translation (8). RPS15A is found to be a responsive gene of transforming growth factor beta (TGF-β) (9). In addition, RPS15A has been reported to promote cell division in actively dividing tissues. In humans, the expression of RPS15A is closely related with cancer progression. Accumulated evidence shows that RPS15A could stimulate cell growth and proliferation in hepatocellular carcinoma (10) and lung adenocarcinoma (11). However, its prognostic significance in CRC remains unclear and there is scarce previous information concerning the possible role of RPS15A in human CRC. In our pilot project, in a lentivirus-based screening of CRC related genes, we identified RPS15A as a potential oncogene in CRC. To further demonstrate the hypothesis, we first studied the correlation between RPS15A expression and the clinicopathological features and prognosis in CRC patients, and then investigated the effects and possible mechanisms of RNAi mediated RPS15A gene knockdown on CRC cells. Ribosomal protein S15A promotes malignant transformation and predicts poor outcome in colorectal cancer through misregulation of p53 signaling pathway JINGwEN CHEN*, YE WEI*, QINGYANG FENG*, LI REN, GuoDoNG HE, wENJu CHANG, DExIANG ZHu, Tuo YI, QI LIN, wENTAo TANG, JIANmIN xu and xINYu QIN Department of General Surgery, Zhongshan Hospital, Fudan university, Shanghai 200032, P.R. China Received December 3, 2015; Accepted January 5, 2016 DoI: 10.3892/ijo.2016.3366 Correspondence to: Dr Jianmin xu or Dr xinyu Qin, Department of General Surgery, Zhongshan Hospital, Fudan university, No. 180 Fenglin Road, Shanghai 200032, P.R. China E-mail: xujmin@aliyun.com E-mail: qin.xinyu@zs-hospital.sh.cn *Contributed equally